Labcorp Launches FDA-Approved Companion Diagnostic to Identify Patients with Ovarian Cancer Eligible for KEYTRUDA® [TheStreet.com]
Labcorp Holdings Inc. (LH)
Last labcorp holdings inc. earnings: 4/29 06:53 am
Check Earnings Report
US:NYSE Investor Relations:
phx.corporate-ir.net/phoenix.zhtml?c=84636&p=irol-irhome
Company Research
Source: TheStreet.com
PR Newswire BURLINGTON, N.C., April 22, 2026 BURLINGTON, N.C. April 22, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the nationwide availability of Agilent Technologies' PD-L1 IHC 22C3 pharmDx , the only companion diagnostic approved by the U.S. Food and Drug Administration (FDA) to identify patients with platinum-resistant ovarian cancer who may be eligible for Merck's KEYTRUDA®. i KEYTRUDA (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) are the first FDA-approved PD-1 inhibitors available as part of a complete treatment regimen for eligible patients with platinum-resistant ovarian cancer. ii Helping Patients Access Critical New Treatment Options Approximately of individuals with ovarian cancer experience recurrence after initial therapy, and many develop resistance to platinum-based chemotherapy, leading to limited treatment options and poor survival outcomes. T
Show less
Read more
Impact Snapshot
Event Time:
LH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LH alerts
High impacting Labcorp Holdings Inc. news events
Weekly update
A roundup of the hottest topics
LH
News
- Labcorp Launches FDA-Approved Companion Diagnostic to Identify Patients with Ovarian Cancer Eligible for KEYTRUDA®PR Newswire
- LH or DHR: Which Is the Better Value Stock Right Now? [Yahoo! Finance]Yahoo! Finance
- UPS plane ordered by controller to abort landing after jet approached runway: "What are you doing?" [CBS News]CBS News
- Labcorp's Rapid Fentanyl Test Clearance And What It Means For Valuation [Yahoo! Finance]Yahoo! Finance
- How Investors Are Reacting To Labcorp (LH) AI-Powered Real-World Data Push In Complex Disease Research [Yahoo! Finance]Yahoo! Finance
LH
Earnings
- 2/17/26 - Beat
LH
Sec Filings
- 4/10/26 - Form ARS
- 4/10/26 - Form DEFA14A
- 4/10/26 - Form DEF
- LH's page on the SEC website